{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:06:20Z","timestamp":1789520780391,"version":"build-2803163510"},"reference-count":138,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbcan.2026.189664","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:55:35Z","timestamp":1784645735000},"page":"189664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of microRNAs in non-small cell lung cancer response and resistance to immune checkpoint inhibitors: From potential biomarkers to therapeutic tools"],"prefix":"10.1016","volume":"1881","author":[{"given":"Sara","family":"Peixoto da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falio","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00facio Lara","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina P.R.","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Helena","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bbcan.2026.189664_bb0005","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung Cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189664_bb0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2026.189664_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2021.118237","article-title":"Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancer","volume":"268","author":"Zhu","year":"2021","journal-title":"Carbohydr. Polym."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189664_bb0020","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6165","key":"10.1016\/j.bbcan.2026.189664_bb0025","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189664_bb0030","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3389\/fonc.2019.01292","article-title":"The role of long non-coding RNAs in immunotherapy resistance","volume":"9","author":"Zhou","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0035","first-page":"1","article-title":"Immunotherapy in non-small cell lung cancer: update and new insights","volume":"7","author":"Mielgo-Rubio","year":"2021","journal-title":"J. Clin. Transl. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189664_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/biom10050666","article-title":"The resistance mechanisms of checkpoint inhibitors in solid tumors","volume":"10","author":"Koustas","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189664_bb0055","series-title":"Immunotherapy","first-page":"65","article-title":"Immunotherapy in lung Cancer: A new age in Cancer treatment","author":"Corrales","year":"2018"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-020-01260-z","article-title":"Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook","volume":"19","author":"Horvath","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189664_bb0070","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with Nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbcan.2026.189664_bb0075","article-title":"The resistance mechanisms of lung cancer immunotherapy","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189664_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1344858","article-title":"MicroRNA-126 selected with broad-spectrum analysis of microRNAs - a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?","volume":"15","author":"Grenda","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189664_bb0090","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189664_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123188","article-title":"Adenosine methylation level of miR-125a-5p promotes anti-PD-1 therapy escape through the regulation of IGSF11\/VSIG3 expression","volume":"15","author":"Bougras-Cartron","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12943-024-02201-w","article-title":"The miR-23a\/27a\/24 - 2 cluster drives immune evasion and resistance to PD-1\/PD-L1 blockade in non-small cell lung cancer","volume":"23","author":"Luo","year":"2024","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189664_bb0105","first-page":"1","article-title":"Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer","volume":"51","author":"Kim","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189664_bb0110","article-title":"CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189664_bb0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2022.10.012","article-title":"Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry-based single-cell analysis","volume":"174","author":"Isomoto","year":"2022","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CCO.0000000000000802","article-title":"Recent advances in primary resistance mechanisms against immune checkpoint inhibitors","volume":"34","author":"Li","year":"2022","journal-title":"Curr. Opin. Oncol."},{"issue":"7718","key":"10.1016\/j.bbcan.2026.189664_bb0125","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"issue":"6371","key":"10.1016\/j.bbcan.2026.189664_bb0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189664_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ph14020089","article-title":"miRNA-based therapeutics in the era of immune-checkpoint inhibitors","volume":"14","author":"Huemer","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189664_bb0140","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1158\/1078-0432.CCR-18-1981","article-title":"Circulating miRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective study","volume":"25","author":"Boeri","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189664_bb0145","first-page":"5193","article-title":"MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer","volume":"17","author":"Grenda","year":"2019","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189664_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020435","article-title":"Machine learning using real-world and translational data to improve treatment selection for NSCLC patients treated with immunotherapy","volume":"14","author":"Prelaj","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189664_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lungcan.2022.09.004","article-title":"Machine learning-based exceptional response prediction of nivolumab monotherapy with circulating microRNAs in non-small cell lung cancer","volume":"173","author":"Zhang","year":"2022","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13148-018-0587-8","article-title":"The role and mechanisms of action of microRNAs in cancer drug resistance","volume":"11","author":"Si","year":"2019","journal-title":"Clin. Epigenetics"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189664_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26031277","article-title":"miRNA signatures in alveolar macrophages related to cigarette smoke: assessment and bioinformatics analysis","volume":"26","author":"Mirra","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189664_bb0170","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O\u2019Brien","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"13","key":"10.1016\/j.bbcan.2026.189664_bb0175","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/1873-3468.70039","article-title":"The power of microRNA regulation\u2014insights into immunity and metabolism","volume":"599","author":"Oliveto","year":"2025","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189664_bb0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2567.2009.03092.x","article-title":"MicroRNA in the immune system, microRNA as an immune system","volume":"127","author":"Lu","year":"2009","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189664_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.528","article-title":"MicroRNAs in non-small cell lung cancer: gene regulation, impact on cancer cellular processes, and therapeutic potential","volume":"7","author":"Petrek","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bbcan.2026.189664_bb0190","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10238-024-01334-y","article-title":"Exploring regulatory mechanisms on miRNAs and their implications in inflammation-related diseases","volume":"24","author":"Nalbant","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189664_bb0200","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/emmm.201100209","article-title":"MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review","volume":"4","author":"Iorio","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189664_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155147","article-title":"Tuning into miRNAs: a comprehensive analysis of their impact on diagnosis, and progression in asthma","volume":"254","author":"Elrebehy","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189664_bb0210","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1183\/09031936.00091513","article-title":"MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD","volume":"43","author":"Molina-Pinelo","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189664_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101573","volume":"8","author":"Natalicchio","year":"2023","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189664_bb0220","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/JTO.0b013e3181a99c77","article-title":"MicroRNAs in the pathogenesis of lung cancer","volume":"4","author":"Wu","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189664_bb0225","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.ygeno.2019.11.019","article-title":"Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer","volume":"112","author":"Fan","year":"2020","journal-title":"Genomics"},{"key":"10.1016\/j.bbcan.2026.189664_bb0230","article-title":"Tissue MicroRNA expression as a predictor of response to immunotherapy in NSCLC patients","volume":"10","author":"Grenda","year":"2020","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189664_bb0235","article-title":"Isolation of cell-free miRNA from biological fluids: influencing factors and methods","volume":"11","author":"Bryzgunova","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0240","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10238-024-01427-8","article-title":"Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab","volume":"24","author":"Genova","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.bbcan.2026.189664_bb0245","first-page":"3","article-title":"Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood","author":"Cheng","year":"2014","journal-title":"J. Extracell. Vesicles"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189664_bb0250","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/JTO.0b013e318299ac32","article-title":"microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer","volume":"8","author":"Cazzoli","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189664_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.673926","article-title":"Circulating miRNAs in serum as biomarkers for early diagnosis of non-small cell lung Cancer","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbcan.2026.189664_bb0260","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2147\/COPD.S457172","article-title":"Blood miRNAs as potential diagnostic biomarkers for chronic obstructive pulmonary disease: a Meta-analysis","volume":"19","author":"Li","year":"2024","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189664_bb0265","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41416-024-02831-3","article-title":"Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC)","volume":"131","author":"Abdipourbozorgbaghi","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0270","doi-asserted-by":"crossref","first-page":"38267","DOI":"10.1038\/s41598-025-21999-z","article-title":"MicroRNA expression in peripheral blood of children with asthma and the role of miR-31-5p in childhood asthma progression","volume":"15","author":"Luo","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189664_bb0275","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/jpm16040179","article-title":"MicroRNAs as diagnostic and therapeutic biomarkers in childhood asthma: a systematic review with bioinformatics analysis","volume":"16","author":"Alrefaey","year":"2026","journal-title":"J. Personal. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0280","doi-asserted-by":"crossref","first-page":"30815","DOI":"10.1038\/s41598-025-15248-6","article-title":"miRNA biomarkers for prognosis and therapy monitoring in a multi-ethnic cohort with SARS-CoV-2 infection","volume":"15","author":"Mustafa","year":"2025","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189664_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051050","article-title":"MicroRNA monitoring in human alveolar macrophages from patients with smoking-related lung diseases: a preliminary study","volume":"12","author":"Mirra","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189664_bb0290","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1073\/pnas.1100048108","article-title":"MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer","volume":"108","author":"Boeri","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbcan.2026.189664_bb0295","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.3390\/biomedicines13123027","article-title":"Sputum Exosomal microRNAs as non-invasive biomarkers in COPD: a cross-sectional study","volume":"13","author":"Kotsiou","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0300","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1038\/s41598-022-10598-x","article-title":"Combining plasma extracellular vesicle let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction","volume":"12","author":"Vadla","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0305","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s43168-020-00021-2","article-title":"MicroRNA genetic signature in non-small cell lung cancer (NSCLC) Egyptian patients","volume":"14","author":"Mansour","year":"2020","journal-title":"Egypt. J. Bronchol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189664_bb0310","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1200\/JCO.2008.19.4134","article-title":"Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non\u2013small-cell lung carcinoma","volume":"27","author":"Lebanony","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189664_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2011.00104","article-title":"MicroRNAs \u2013 important molecules in lung Cancer research","volume":"2","author":"Leidinger","year":"2012","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0320","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1756-9966-29-75","article-title":"MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs","volume":"29","author":"Du","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189664_bb0325","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7150\/ijbs.22243","article-title":"MicroRNAs associated with therapy of non-small cell lung cancer","volume":"14","author":"Lu","year":"2018","journal-title":"Int. J. Biol. Sci."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189664_bb0330","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jtho.2020.05.022","article-title":"Circulating MicroRNAs and extracellular vesicle-containing MicroRNAs as response biomarkers of anti-programmed cell death protein 1 or programmed death-ligand 1 therapy in NSCLC","volume":"15","author":"Shukuya","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189664_bb0335","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189664_bb0340","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdv090.2","article-title":"P1.02 - MesomiR 1: a phase I study of TargomiRs in patients with refractory malignant pleural mesothelioma (MPM) and lung cancer (NSCLC)","volume":"26","author":"van Zandwijk","year":"2015","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189664_bb0345","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2217\/epi-2016-0035","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"Reid","year":"2016","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0350","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41420-024-02182-1","article-title":"The miRNA and PD-1\/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer","volume":"10","author":"Yadav","year":"2024","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189664_bb0355","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: from cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0360","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12935-024-03293-6","article-title":"MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1\/PD-L1 and CTLA-4 pathways","volume":"24","author":"Zabeti Touchaei","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2026.189664_bb0365","article-title":"Frontiers of MicroRNA signature in non-small cell lung cancer","volume":"9","author":"Zhu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0370","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12943-019-1111-2","article-title":"Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"22","key":"10.1016\/j.bbcan.2026.189664_bb0375","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/aging.203576","article-title":"Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p\/EGFR axis","volume":"13","author":"Ge","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0380","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-021-01448-x","article-title":"Cancer cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934\/SHP2 axis in NSCLC","volume":"20","author":"Chen","year":"2021","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189664_bb0385","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41419-020-03224-z","article-title":"Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells","volume":"11","author":"Guyon","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0390","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-022-01586-w","article-title":"The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p\/CARM1 axis","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189664_bb0395","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41419-021-04095-8","article-title":"hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189664_bb0400","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cpt.2024.11.003","article-title":"Circular RNA vaccines: pioneering the next-gen cancer immunotherapy","volume":"3","author":"Das","year":"2025","journal-title":"Cancer Pathogen. Therapy"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0405","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-021-01398-4","article-title":"N(6)-methyladenosine-modified circIGF2BP3 inhibits CD8(+) T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer","volume":"20","author":"Liu","year":"2021","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0410","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00262-022-03235-z","article-title":"Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1\/PD-L1 checkpoint","volume":"72","author":"Lei","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0415","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0420","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41420-021-00527-8","article-title":"MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3","volume":"7","author":"Shao","year":"2021","journal-title":"Cell Death Discov."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189664_bb0425","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1111\/cas.15921","article-title":"MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma","volume":"114","author":"Nakanishi","year":"2023","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189664_bb0430","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s12033-021-00379-8","article-title":"MicroRNA-4458 regulates PD-L1 expression to enhance anti-tumor immunity in NSCLC via targeting STAT3","volume":"63","author":"Liu","year":"2021","journal-title":"Mol. Biotechnol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189664_bb0435","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1111\/jcmm.13657","article-title":"The miR-3127-5p\/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer","volume":"22","author":"Tang","year":"2018","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0440","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1620\/tjem.2022.J013","article-title":"Increased PD-L1 expression in acquired cisplatin-resistant lung Cancer cells via Mir-181a","volume":"257","author":"Chen","year":"2022","journal-title":"Tohoku J. Exp. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189664_bb0445","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2015.10","article-title":"The clinical relevance of the miR-197\/CKS1B\/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer","volume":"23","author":"Fujita","year":"2015","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0450","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/21655979.2021.2014617","article-title":"microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1","volume":"13","author":"Jiang","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.bbcan.2026.189664_bb0455","article-title":"Tracking the response to immunotherapy: blood microRNA dynamics in patients with advanced non-small cell lung cancer","volume":"9","author":"Chiaruttini","year":"2025","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0460","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41698-022-00262-y","article-title":"A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy","volume":"6","author":"Rajakumar","year":"2022","journal-title":"NPJ Precis Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0465","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/s41598-025-85793-7","article-title":"MicroRNA-150-3p enhances the antitumour effects of CGP57380 and is associated with a favourable prognosis in non-small cell lung cancer","volume":"15","author":"Zheng","year":"2025","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189664_bb0470","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189664_bb0475","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189664_bb0480","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.molmed.2015.08.002","article-title":"Intercellular transfer of Cancer drug resistance traits by extracellular vesicles","volume":"21","author":"Sousa","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189664_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100833","article-title":"The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells","volume":"62","author":"Xavier","year":"2022","journal-title":"Drug Resist. Updat."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189664_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051141","article-title":"The role of extracellular vesicles in the hallmarks of Cancer and drug resistance","volume":"9","author":"Xavier","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189664_bb0495","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Y\u00e1\u00f1ez-M\u00f3","year":"2015","journal-title":"J. Extracell. Vesicles"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189664_bb0500","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010200","article-title":"Deep sequencing analysis reveals distinctive non-coding RNAs when comparing tumor multidrug-resistant cells and extracellular vesicles with drug-sensitive counterparts","volume":"12","author":"Sousa","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189664_bb0510","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/cancers13040585","article-title":"Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors","volume":"13","author":"Brocco","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189664_bb0515","doi-asserted-by":"crossref","first-page":"S825","DOI":"10.1016\/j.annonc.2020.08.1591","article-title":"1277P an exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer","volume":"31","author":"Genova","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0520","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000376","article-title":"Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR \/ ALK wild-type advanced non-small cell lung cancer","volume":"8","author":"Peng","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189664_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1540906","article-title":"Serum extracellular vesicle microRNAs as potential biomarkers to predict pembrolizumab response and prognosis in metastatic non-small cell lung cancer patients","volume":"16","author":"Lamorte","year":"2025","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189664_bb0530","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084533","article-title":"Novel blood biomarkers for response prediction and monitoring of stereotactic ablative radiotherapy and immunotherapy in metastatic Oligoprogressive lung cancer","volume":"25","author":"Zafra","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189664_bb0535","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.tibtech.2020.05.012","article-title":"Technologies and standardization in research on extracellular vesicles","volume":"38","author":"Gandham","year":"2020","journal-title":"Trends Biotechnol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189664_bb0540","doi-asserted-by":"crossref","DOI":"10.1002\/jex2.76","article-title":"Standardising the preanalytical reporting of biospecimens to improve reproducibility in extracellular vesicle research - a GEIVEX study","volume":"2","author":"L\u00f3pez-Guerrero","year":"2023","journal-title":"J. Extracell Biol."},{"key":"10.1016\/j.bbcan.2026.189664_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2935","article-title":"212P extracellular vesicle miRNA as effective biomarkers for predicting antitumor efficacy in lung adenocarcinoma treated with chemotherapy and checkpoint blockade","volume":"34","author":"Sun","year":"2023","journal-title":"Ann. Oncol."},{"issue":"3\u20135","key":"10.1016\/j.bbcan.2026.189664_bb0550","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drup.2013.05.001","article-title":"MicroRNAs as therapeutic targets in chemoresistance","volume":"16","author":"Garofalo","year":"2013","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0555","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41544-019-0024-y","article-title":"Recent progress in microRNA-based delivery systems for the treatment of human disease","volume":"1","author":"Fu","year":"2019","journal-title":"ExRNA"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189664_bb0560","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/cas.13965","article-title":"Development of miRNA-based therapeutic approaches for cancer patients","volume":"110","author":"Takahashi","year":"2019","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189664_bb0565","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520904847","article-title":"MicroRNA-34c-3p target inhibiting NOTCH1 suppresses chemosensitivity and metastasis of non-small cell lung cancer","volume":"48","author":"Yang","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.bbcan.2026.189664_bb0570","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jare.2020.08.012","article-title":"Therapeutic advances of miRNAs: a preclinical and clinical update","volume":"28","author":"Chakraborty","year":"2021","journal-title":"J. Adv. Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189664_bb0575","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1021\/acs.molpharmaceut.3c01040","article-title":"Immunotherapy study on non-small-cell lung Cancer (NSCLC) combined with cytotoxic T cells and miRNA34a","volume":"21","author":"Pandey","year":"2024","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189664_bb0580","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189664_bb0585","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189664_bb0590","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.omtn.2023.02.031","article-title":"Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment","volume":"32","author":"Yan","year":"2023","journal-title":"Mol. Therapy - Nucleic Acids"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189664_bb0595","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thorax-2024-221793","article-title":"Advanced MicroRNA delivery for lung inflammatory therapy: surfactant protein a controls cellular internalisation and degradation of extracellular vesicles","volume":"80","author":"Kim","year":"2025","journal-title":"Thorax"},{"key":"10.1016\/j.bbcan.2026.189664_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145463","article-title":"Nanocarriers for microRNA delivery: a review of applied platforms and perspectives","volume":"319","author":"Alahverdi","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbcan.2026.189664_bb0605","article-title":"Aerosolized miR-138-5p and miR-200c targets PD-L1 for lung cancer prevention","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189664_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114113","article-title":"RNAi-based therapeutics and tumor targeted delivery in cancer","volume":"182","author":"Kara","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189664_bb0615","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1021\/acs.molpharmaceut.4c00871","article-title":"Non-viral RNA therapies for non-small cell lung cancer and their corresponding clinical trials","volume":"22","author":"Tiwade","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbcan.2026.189664_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.105413","article-title":"STAR particles as potential game-changer in drug delivery and biological processes: moving beyond conventional nanoparticles","volume":"93","author":"Singh","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189664_bb0625","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1021\/acsabm.5c00489","article-title":"Nanotechnology-enhanced siRNA delivery: revolutionizing Cancer therapy","volume":"8","author":"Esmaeilpour","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189664_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102057","article-title":"Challenges and opportunities in microRNA-based cancer therapeutics","volume":"6","author":"Ju","year":"2025","journal-title":"Cell Reports Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189664_bb0635","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/0284186X.2018.1465585","article-title":"Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab","volume":"57","author":"Halvorsen","year":"2018","journal-title":"Acta Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189664_bb0640","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.21037\/tlcr-2025-636","article-title":"Stage- and smoking-associated microRNA expression in lung adenocarcinoma","volume":"14","author":"Huang","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"issue":"28","key":"10.1016\/j.bbcan.2026.189664_bb0645","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41388-024-03076-3","article-title":"MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances","volume":"43","author":"Metcalf","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189664_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215774","article-title":"Elevated circASCC3 limits antitumor immunity by sponging miR-432-5p to upregulate C5a in non-small cell lung cancer","volume":"543","author":"Gao","year":"2022","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189664_bb0655","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41420-022-00983-w","article-title":"circ_0004140 promotes LUAD tumor progression and immune resistance through circ_0004140\/miR-1184\/CCL22 axis","volume":"8","author":"Liu","year":"2022","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189664_bb0660","first-page":"261","article-title":"Circular RNA drives resistance to anti-PD-1 immunotherapy by regulating the miR-30a-5p\/SOX4 axis in non-small cell lung cancer","volume":"5","author":"Wu","year":"2022","journal-title":"Cancer Drug Resist."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189664_bb0665","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1111\/1759-7714.13653","article-title":"MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer","volume":"11","author":"Katakura","year":"2020","journal-title":"Thorac Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189664_bb0670","article-title":"Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab","volume":"7","author":"Costantini","year":"2018","journal-title":"Oncoimmunology"},{"issue":"19","key":"10.1016\/j.bbcan.2026.189664_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194739","article-title":"Plasma-based microRNA expression analysis in advanced stage NSCLC patients treated with Nivolumab","volume":"14","author":"Monastirioti","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189664_bb0680","article-title":"Brief report: a blood-based MicroRNA complementary diagnostic predicts immunotherapy efficacy in advanced-Sta ge NSCLC with high programmed death-ligand 1 express ion","volume":"3","author":"Rajakumar","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.bbcan.2026.189664_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147177","article-title":"Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1\/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer","volume":"857","author":"Hisakane","year":"2023","journal-title":"Gene"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189664_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102435","article-title":"Large-scale profiling of extracellular vesicles identified miR-625-5p as a novel biomarker of immunotherapy response in advanced non-small-cell lung Cancer patients","volume":"14","author":"Pantano","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:17:56Z","timestamp":1789517876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":138,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0304419X26001368"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189664","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of microRNAs in non-small cell lung cancer response and resistance to immune checkpoint inhibitors: From potential biomarkers to therapeutic tools","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189664"}}